373 related articles for article (PubMed ID: 10470199)
1. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
2. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
Oremek GM; Teigelkamp S; Kramer W; Eigenbrodt E; Usadel KH
Anticancer Res; 1999; 19(4A):2599-601. PubMed ID: 10470201
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
[TBL] [Abstract][Full Text] [Related]
4. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.
Oremek GM; Sapoutzis N; Kramer W; Bickeböller R; Jonas D
Anticancer Res; 2000; 20(6D):5095-8. PubMed ID: 11326675
[TBL] [Abstract][Full Text] [Related]
5. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma.
Weinberger R; Appel B; Stein A; Metz Y; Neheman A; Barak M
Eur J Cancer Care (Engl); 2007 Jul; 16(4):333-7. PubMed ID: 17587357
[TBL] [Abstract][Full Text] [Related]
6. Quantitative detection of tumor M2-PK in serum and plasma.
Hugo F; Fischer G; Eigenbrodt E
Anticancer Res; 1999; 19(4A):2753-7. PubMed ID: 10470235
[TBL] [Abstract][Full Text] [Related]
7. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK).
Oremek GM; Gerstmeier F; Sauer-Eppel H; Sapoutzis N; Wechsel HW
Anticancer Res; 2003; 23(2A):1127-30. PubMed ID: 12820359
[TBL] [Abstract][Full Text] [Related]
8. [Immunohistochemical demonstration of L- and M2-pyruvate kinase in primary renal cell carcinomas and their metastases].
Fischer G; Holzrichter S; Reinacher M; Heinrichs M; Dembowski J; Eigenbrodt E
Verh Dtsch Ges Pathol; 1989; 73():422-7. PubMed ID: 2482632
[TBL] [Abstract][Full Text] [Related]
9. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells.
Eigenbrodt E; Reinacher M; Scheefers-Borchel U; Scheefers H; Friis R
Crit Rev Oncog; 1992; 3(1-2):91-115. PubMed ID: 1532331
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
Kaura B; Bagga R; Patel FD
J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
[TBL] [Abstract][Full Text] [Related]
11. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas.
Eigenbrodt E; Basenau D; Holthusen S; Mazurek S; Fischer G
Anticancer Res; 1997; 17(4B):3153-6. PubMed ID: 9329624
[TBL] [Abstract][Full Text] [Related]
12. Value of tumor M2-PK in thyroid carcinoma: a pilot study.
Bena-Boupda NF; Rezai SS; Klett R; Eigenbrodt E; Bauer R
Anticancer Res; 2003; 23(6D):5237-40. PubMed ID: 14981996
[TBL] [Abstract][Full Text] [Related]
13. Tumor M2-PK levels in haematological malignancies.
Oremek GM; Rox S; Mitrou P; Sapoutzis N; Sauer-Eppel H
Anticancer Res; 2003; 23(2A):1135-8. PubMed ID: 12820361
[TBL] [Abstract][Full Text] [Related]
14. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S
Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
[TBL] [Abstract][Full Text] [Related]
15. Tumor type M2 pyruvate kinase expression in advanced breast cancer.
Lüftner D; Mesterharm J; Akrivakis C; Geppert R; Petrides PE; Wernecke KD; Possinger K
Anticancer Res; 2000; 20(6D):5077-82. PubMed ID: 11326672
[TBL] [Abstract][Full Text] [Related]
16. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
Kumar Y; Tapuria N; Kirmani N; Davidson BR
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.
Gayed BA; Gillen J; Christie A; Peña-Llopis S; Xie XJ; Yan J; Karam JA; Raj G; Sagalowsky AI; Lotan Y; Margulis V; Brugarolas J
BMC Urol; 2015 Apr; 15():24. PubMed ID: 25885592
[TBL] [Abstract][Full Text] [Related]
18. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
[TBL] [Abstract][Full Text] [Related]
19. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
Ervens J; Fuchs H; Niemann VT; Hoffmeister B
J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
[TBL] [Abstract][Full Text] [Related]
20. [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Urologe A; 2000 Nov; 39(6):554-6. PubMed ID: 11138278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]